Medication info
Rosuvastatin/Amlodipine Tablets 20/10 mg

Rosuvastatin/Amlodipine Tablets 20/10 mg

Prescription medicationTabletOral
Ingredient · strength
Rosuvastatin Calcium›20.8mg / 1 tabletAmlodipine Besylate›13.889mg / 1 tablet
Manufacturer / importer
Yuhan Corporation
Appearance
Yellow round film-coated tablet
Packaging
30 tablets/bottle
Approval status
Active

MFDS item code 201803559 · Approved 2018.08.31

Summary

Main use
Treatment of dyslipidemia and hypertension; treatment and prevention of cardiovascular diseases (angina, etc.)
Who takes it
Adults
Adult dose
This medicine is for use in adults only. The dose should be individualized for each patient based on the efficacy and tolerability of each component, amlodipine and rosuvastatin. ○ Amlodipine Adults: Administer 5 mg of amlodipine orally once daily; the dose may be increased to a maximum of 10 mg daily according to the patient's response. Adjust the dose as appropriate according to symptoms. ○ Rosuvastatin 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily; if a greater reduction in LDL cholesterol is needed, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 milligrams once daily, which is adequate for most patients. Adjust the maintenance dose as appropriate at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and patient response; the dose may be increased to a maximum of 20 milligrams daily. 2. Elderly patients: No dose adjustment is necessary. 3. Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Use particular caution when administering 20 mg of this medicine to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function tests should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 5. Race: Because systemic exposure to rosuvastatin is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose of rosuvastatin is contraindicated in some of these patients. Patients taking amlodipine and rosuvastatin concomitantly may switch to this medicine (a combination product containing the same amount of each active ingredient) for convenience.

Ingredients

Manufacturer
Yuhan Corporation

Efficacy & effects

Treatment of dyslipidemia and hypertension; treatment and prevention of cardiovascular diseases (angina, etc.)

  • Hypertension
  • fixed occlusion of coronary arteries
  • coronary vasospasm
  • vascular constriction
  • myocardial ischemia
  • primary hypercholesterolemia
  • heterozygous familial hypercholesterolemia
  • mixed hyperlipidemia
  • homozygous familial hypercholesterolemia
  • hypercholesterolemia
  • primary dysbetalipoproteinemia
  • elevated high-sensitivity C-reactive protein
View approved original text

This medication is used for patients who need to take both amlodipine and rosuvastatin. Amlodipine helps treat hypertension and myocardial ischemia caused by stable and variant angina, and reduces the risk of angina and coronary revascularization in patients with coronary artery disease. Rosuvastatin is effective in improving hypercholesterolemia and dyslipidemia, and is used as an adjunct to dietary therapy, especially in patients with familial hypercholesterolemia. It also plays a role in reducing the risk of cardiovascular events, including stroke, myocardial infarction, and revascularization procedures. Thus, both medications are used to improve cardiovascular health by controlling blood pressure and cholesterol levels.

How to take

Adult dose

This medicine is for use in adults only. The dose should be individualized for each patient based on the efficacy and tolerability of each component, amlodipine and rosuvastatin. ○ Amlodipine Adults: Administer 5 mg of amlodipine orally once daily; the dose may be increased to a maximum of 10 mg daily according to the patient's response. Adjust the dose as appropriate according to symptoms. ○ Rosuvastatin 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily; if a greater reduction in LDL cholesterol is needed, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 milligrams once daily, which is adequate for most patients. Adjust the maintenance dose as appropriate at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and patient response; the dose may be increased to a maximum of 20 milligrams daily. 2. Elderly patients: No dose adjustment is necessary. 3. Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Use particular caution when administering 20 mg of this medicine to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function tests should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 5. Race: Because systemic exposure to rosuvastatin is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose of rosuvastatin is contraindicated in some of these patients. Patients taking amlodipine and rosuvastatin concomitantly may switch to this medicine (a combination product containing the same amount of each active ingredient) for convenience.

Precautions

This medication should not be used in patients who are allergic to specific ingredients. It should not be administered to pregnant or potentially pregnant women, or nursing mothers, and should only be used with caution in cases where the likelihood of pregnancy is deemed low. It should be avoided in patients with severely impaired liver function or active liver disease, severe aortic stenosis, shock state, myopathy, and in patients who are taking certain medications concurrently. This medication is also not recommended for patients with severely impaired kidney function. Particular caution is required for patients with a history of muscle disease or at risk of muscle toxicity, and should a patient experience muscle pain or weakness, immediate consultation with a healthcare professional is necessary. During treatment, it is advisable to regularly monitor liver enzyme tests, and if symptoms of liver dysfunction arise, the medication should be immediately discontinued. Dosing adjustments and monitoring should be done carefully for the elderly, those with renal failure, and patients with low blood pressure. This medication may interact with other drugs, so it is essential to inform healthcare providers of any current medications being taken. It should not be used during pregnancy or nursing, and appropriate contraceptive measures should be taken if planning to conceive. Safety and efficacy have not been established for pediatric use, so it is advisable not to administer it to children. In case of overdose, immediate visit to a medical institution for appropriate treatment is necessary, and the medication should be kept out of reach of children.

Side effects

Peripheral edema, chest pain, wrist fracture, gout, dizziness, headache, flushing, fatigue, swelling, palpitations, vertigo, drowsiness, abdominal pain, nausea, weakness, lethargy, pain, weight gain, weight loss, tension increase, sensory loss, paresthesia, peripheral neuropathy, syncope, taste disturbance, tremor, extrapyramidal disorder, erectile dysfunction, gynecomastia, change in bowel habits, dry mouth, dyspepsia, gastritis, gingival hypertrophy, pancreatitis, vomiting, hyperglycemia, arthralgia, low back pain, muscle cramps, myalgia, leukopenia, thrombocytopenia, insomnia, mood changes, cough, dyspnea, rhinitis, alopecia, hyperhidrosis, purpura, skin discoloration, urticaria, toxic epidermal necrolysis, tinnitus, visual disturbances, increased urinary frequency, urinary dysfunction, nocturia, hepatitis, jaundice, elevated liver enzymes, pruritus, rash, vascular edema, erythema multiforme, myocardial infarction, arrhythmia, chest pain, hypotension, SA block, AV block, abdominal discomfort, precordial pain, diarrhea, loose stools, constipation, skin flushing, maculopapular rash, heaviness, warmth, glucose tolerance decrease, weakness, vascular edema, hypersensitivity reaction, diabetes, headache, dizziness, constipation, nausea, abdominal pain, pancreatitis, itching, rash, urticaria, myalgia, myopathy, rhabdomyolysis, myasthenia, proteinuria, hematuria, multiple neuropathy, memory loss, peripheral neuropathy, diarrhea, thrombocytopenia, jaundice, hepatitis, increased transaminases, Stevens-Johnson syndrome, drug reaction with eosinophilia and systemic symptoms, lupus-like syndrome, muscle rupture, arthralgia, immune-mediated necrotizing myopathy, hematuria, edema, depression, sleep disorders, interstitial lung disease, sexual dysfunction, gynecomastia, fatal liver failure, non-fatal liver failure, cognitive impairment, severe muscle weakness, ocular muscle weakness, elevated ALT, elevated CK, elevated AST, numbness, paresthesia, chest discomfort, loss of appetite, abdominal distension, syncope, generalized pain, muscle cramps, erectile dysfunction, acute kidney failure, oliguria, increased serum creatinine

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to avoid exposure to air or moisture. It is recommended to keep the storage temperature between 1 and 30 degrees Celsius.

Appearance and packaging

Appearance

Yellow round film-coated tablet

Package unit

30 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.